{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/279920996"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "We expect to incur additional losses and negative cash flows in the future, and these losses may continue or increase in part due to anticipated levels of expenses for research and development, particularly clinical development and expansion of our clinical and scientific capabilities to support ongoing development of our programs." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "arraybiopharma.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/130488310"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/279920996" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/881769"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/279920996"] } } }
